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Abstract
Background: Hospital-acquired and ventilator-associated pneumonias (HAP and VAP) are common in critical care
and can be life-threatening. Rapid microbiological diagnostics, linked to an algorithm to translate their results into
antibiotic choices, could simultaneously improve patient outcomes and antimicrobial stewardship.
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Methods: The INHALE Randomised Controlled Trial is a multi-centre, parallel study exploring the potential of the
BioFire FilmArray molecular diagnostic to guide antibiotic treatment of HAP/VAP in intensive care units (ICU); it
identifies pathogens and key antibiotic resistance in around 90 min. The comparator is standard care whereby the
patient receives empirical antibiotics until microbiological culture results become available, typically after 48–72 h.
Adult and paediatric ICU patients are eligible if they are about to receive antibiotics for a suspected lower
respiratory infection (including HAP/VAP) for the first time or a change in antibiotic because of a deteriorating
clinical condition. Breathing spontaneously or intubated, they must have been hospitalised for 48 h or more.
Patients are randomised 1:1 to receive either antibiotics guided by the FilmArray molecular diagnostic and its trial-
based prescribing algorithm or standard care, meaning empirical antibiotics based on local policy, adapted
subsequently based upon local microbiology culture results. Co-primary outcomes are (i) non-inferiority in clinical
cure of pneumonia at 14 days post-randomisation and (ii) superiority in antimicrobial stewardship at 24 h post-
randomisation (defined as % of patients on active and proportionate antibiotics). Secondary outcomes include
further stewardship reviews; length of ICU stay; co-morbidity indicators, including septic shock, change in sequential
organ failure assessment scores, and secondary pneumonias; ventilator-free days; adverse events over 21 days; all-
cause mortality; and total antibiotic usage. Both cost-effectiveness of the molecular diagnostic-guided therapy and
behavioural aspects determining antibiotic prescribing are being explored. A sample size of 552 will be required to
detect clinically significant results with 90% power and 5% significance for the co-primary outcomes.
Discussion: This trial will test whether the potential merits of rapid molecular diagnostics for pathogen and
resistance detection in HAP/VAP are realised in patient outcomes and/or improved antibiotic stewardship.
Trial registration: ISRCTN Registry ISRCTN16483855. Retrospectively registered on 15 July 2019
Keywords: Antibiotic stewardship, Randomised controlled trial, Hospital-acquired pneumonia, Ventilator-associated
pneumonia
Background
Hospital-acquired and ventilator-associated pneumonias
(HAP and VAP) are medically important owing to their
frequency and high mortality and because they drive the
use of broad-spectrum antibiotics. In the United King-
dom (UK), VAP occurs in 9–27% of ventilated patients,
with an incidence of 5 cases/1000 ventilator days [1].
The cost is high: Edwards et al. [2] estimated around
£19–20K per patient for severe pneumonia, even at 2008
prices.
Most ventilated patients are in intensive care, which
has heavier antibiotic use and selection pressures than
other hospital sites, with correspondingly greater resist-
ance [3]. Crucially, in context, pulmonary infections ac-
count for approximately 50% of all ICU antibiotic use [1,
4], underscoring their contribution to these antibiotic
pressures.
Timely treatment is crucial to outcome in HAP and
VAP, with mortality increased if antibiotics are with-
held or delayed [5]. Accordingly, antimicrobial
chemotherapy is begun empirically, at clinical diagno-
sis, with the agents used being selected based on
guidelines; local resistance rates; and patient risk fac-
tors for resistant bacteria (e.g. other recent antibiotics
and duration of hospitalisation(s)). This approach re-
flects the fact that it takes 48–72 h to grow and test
the bacteria causing the infection by a standard of
care microbiology, delaying the opportunity to match
the antibiotic to the pathogen present.
Treatment inadequacy, because the pathogen proves
resistant to the empirical agent(s), is associated with in-
creased mortality [6]. Consequently, fears of resistance-
associated failure create pressure to empirically prescribe
the broadest-spectrum antibiotics, including carbapen-
ems [7] as recorded in a recent NHS longitudinal ana-
lysis [8]. This approach is argued to increase survival
and to have health economic benefits (e.g. shorter time
in ICU), including in NHS settings [2] but amounts to
poor stewardship. Many patients with susceptible patho-
gens are given unnecessarily broad-spectrum antibiotics,
and these exert pressure on the gut flora, favouring the
overgrowth of drug-resistant bacteria, which constitute a
reservoir of future opportunist pathogens.
Improved infection control has reduced the NHS’s
burden of methicillin-resistant Staphylococcus aureus
(MRSA) and Clostridium difficile, but resistance rates
among Gram-negative bacteria are rising and, on an
international basis, are doing so alarmingly, e.g. with an
explosive increase of K. pneumoniae with KPC carbape-
nemases in Italy and Greece and Enterobacterales with
NDM carbapenemases in the Indian subcontinent [9].
Most carbapenemase producers are susceptible in vitro
only to a few antibiotics, e.g. colistin and tigecycline, that
have significant toxicity and efficacy limitations.
High et al. Trials          (2021) 22:680 Page 2 of 12
The conventional approach to overcoming resistance
has been the development of new antibiotics, but the
flow of these has slowed, reflecting the difficulty of
discovering, developing and licensing them and the low-
return on investment. Although new antibiotics, cover-
ing some multi-resistant Gram-negative pathogens, are
beginning to reach the market, none wholly overcomes
the existing resistance and all are vulnerable to new re-
sistance. Restrictive stewardship conserves existing anti-
biotics, but at a risk of denying effective treatment to
seriously ill patients. As recognised in the Chief Medical
Officer’s (CMO) Report [10], it is vital to find alternative,
evidence-based models to guide the use of both new and
established antibiotics. These logically include rapid
diagnostics, and in his 2016 report commissioned by the
UK government, O’Neill [11] recommended that, by
2020, antibiotics should only be prescribed if informed
by data and testing technology.
In principle, and even without rapid diagnostics, the
broad-spectrum empirical therapy initiated when HAP
or VAP is clinically diagnosed should be de-escalated
to narrower-spectrum therapy once the pathogen is
identified and its resistances determined by the
microbiology laboratory, a process that typically takes
48–72 h. This strategy, sometimes dubbed ‘start smart,
then focus’, has developed over 70 years, and its time-
scales depend upon the speed of bacterial growth and
testing in the microbiology laboratory. Although
sound in principle, this approach has three major
limitations.
First, as already noted, it leads to over-treatment of
the many patients with susceptible pathogens, unneces-
sarily increasing the pressure on the gut flora.
Secondly, many patients with clinically diagnosed in-
fections have no pathogen grown. This proportion is as
high as 70% in pneumonia [12]. Failure to grow a patho-
gen may reflect suppression of growth by antibiotic(s)
already given to the patient, inappropriate culture tech-
nique or a purely viral aetiology. Since their pathogens
remain undefined, and with the threat of increased mor-
tality due to under-treatment, these patients often spend
prolonged periods on broad-spectrum empirical agents,
including empirical carbapenems. This raises the contin-
gent risk of side effects and selection of a resistant gut
flora. Even when microbiology results become available,
indicating susceptible pathogens, clinicians frequently
fail to de-escalate broad-spectrum therapy. This can be
unintentional, reflecting other aspects of the critically ill
patient’s treatment being prioritised. It can also be
intentional, especially when the patient is doing well
clinically, with doctors reluctant to change a ‘winning’
therapy lest the patient deteriorates again [13]. These is-
sues are exacerbated by long waits for microbiology
results.
Thirdly, even with broad-spectrum agents, empirical
therapy is likely to prove inadequate in patients with
unusually resistant pathogens, whose mortality risk is
thereby increased in severe infection [14]. Peralta
et al. [15] found that the risk of empirical treatment
proving to be inappropriate rose from 3% for patients
with pathogens lacking resistance to 35% for those
resistant to 3 or more antibiotic classes, with a com-
mensurate increase in deaths. In normal (i.e. non-
pandemic) circumstances, such under-treatment is
most likely in centres providing tertiary care and
serving mobile populations with extensive travel to
countries with higher resistance rates (e.g. many cen-
tral London teaching hospitals) and in those private
hospitals that treat patients from regions where resist-
ance is highly prevalent (e.g. in the Middle East). In
the longer term, the risk of under-treatment is likely
to increase and become more widespread, especially
if, as seems likely, the accumulation of resistance con-
tinues to outstrip antibiotic development, particularly
against Gram-negative opportunist pathogens.
Molecular microbiological diagnostics offer a potential
route to overcoming these limitations by identifying the
pathogens and their resistances in hours instead of days,
allowing immediate targeted therapy or, at least, much
earlier therapeutic refinement. Several automated, poly-
merase chain reaction (PCR)-based pathogen and resist-
ance detection platforms are now available for
microbiological evaluation of HAP and VAP patients,
but no data exist on whether these offer advantages in
respect of clinical outcomes, or if they are cost-effective.
The INHALE Randomised Controlled Trial (RCT) de-
tailed here is Work Package 3 (WP3) of the NIHR-
funded INHALE Research Programme. In WPs 1 and 2,
three rapid diagnostic systems—the PCR-based BioFire
FilmArray, Curetis Unyvero platforms and rapid sequen-
cing with the Oxford Nanopore Technologies Min-
ION—were evaluated on respiratory specimens from
ICU patients ([16, 17]. Based on the results, the FilmAr-
ray Pneumonia Panel (the ‘FilmArray test’) was selected
as the best performing test to carry forward into the
present RCT. Prior evaluation of the FilmArray test was
extremely limited at the start of this work, with no UK
study. In addition, and of particular importance, there
was (and is) no evidence base to direct how and where
to deploy such a platform within clinical pathways for
maximum efficiency and value for money. Whether, how
and why physicians might welcome such tests—which
deliver swifter results at the expense of a more restricted
range of bacterial pathogens and (especially) resistances
detected—were unknown. Addressing these behavioural
factors of ‘acceptability’ is essential for effective imple-
mentation, assuming the present trial finds the FilmAr-
ray test advantageous.
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Accordingly, the INHALE RCT is a two-armed study
with two co-primary outcomes: non-inferiority in clinical
cure of pneumonia at 14 days post-randomisation and
superiority in anti-microbial stewardship at 24 h post-
randomisation. In the intervention arm, therapy for
HAP/VAP will be guided by the FilmArray test, under-
taken within ICUs rather than in a laboratory; the results
are linked to an algorithm to translate its outputs into
treatment guidance. In the control arm, patients will re-
ceive standard empirical antibiotics, according to the
local prescribing policy. Both arms allow further refine-
ment of therapy once conventional culture-based results
become available.
Behavioural analysis will (i) compare the clinicians’
decision-making with and without the FilmArray test,
(ii) explore clinicians’ barriers to adopting molecular
diagnostics and (iii) provide evidence-based recommen-
dations for how to overcome these. An economic ana-
lysis will review the cost-effectiveness implications.
Objectives
The overall trial aim is to show that clinical and safety
outcomes for patients whose treatment is guided by the
FilmArray test molecular diagnostic are non-inferior
compared to standard care, but that altered prescribing
leads to improved antimicrobial stewardship.
Primary objectives
The co-primary objectives are as follows:
1. To determine whether there is non-inferiority in
clinical cure of pneumonia at 14 days post-
randomisation between patients treated according
to the FilmArray test’s molecular results plus trial-
based prescribing algorithm versus those treated
with standard care.
2. To determine whether there is an improvement in
antimicrobial stewardship at 24 h post-
randomisation for participants treated according to
the FilmArray test versus those treated with stand-
ard care. In context, antimicrobial stewardship is
defined as the receipt of active and proportionate
treatment.
Since these are co-primary objectives, the study will be
declared to have met its primary objectives only if the
FilmArray test is found to be both non-inferior to stand-
ard care in terms of clinical cure and also provides im-
provements in antimicrobial stewardship.
Secondary objectives
FilmArray and standard care arms additionally will be
compared to determine whether:
1. There is a difference in the number of participants
receiving an appropriate antibiotic at 24 and 72 h
post-randomisation
2. There is a difference between the two groups in
total antibiotic use over the 21-day study period
3. The FilmArray test plus algorithm is more cost-
effective than the standard care at 21 days post-
randomisation
4. There are any differences in antibiotic-associated
adverse events (e.g. C. difficile infection) between
the two groups within 21 days of randomisation
5. There are changes in organ dysfunction scores
between the two groups at day 7 post-
randomisation
6. ICU/critical care unit (CCU) length of stay, septic
shock rates, or mortality rates are decreased (or
increased) by the intervention compared to the
standard care
7. There is an increase in ventilator-free days for ven-
tilated participants in the intervention group
8. There are differences between the groups in the




INHALE WP3 is a multi-centre, open-labelled, parallel,
randomised controlled trial exploring the potential im-
pact of the FilmArray rapid molecular diagnostics
coupled with a prescribing algorithm, aiming for non-
inferiority in clinical cure of pneumonia and superiority
with regard to antimicrobial stewardship, compared with
standard care. Additional file 1: Figure S1 illustrates the
design. Participants are randomised in a 1:1 ratio cen-
trally, via a Research Electronic Data Capture (REDCap)
[18, 19] web-based randomisation system, to receive ei-
ther the intervention plus standard care or standard care
alone. Randomisation is stratified by site using permuted
block allocation of randomly varying block lengths; con-
cealment of allocation is guaranteed by using the web-
based system. All participants remain in the trial for up
to 28 days for data collection. Once a participant is ran-
domised, the trial is open-label, meaning clinicians and
all study team members will know which group a par-
ticipant is in. The participant will also be informed upon
request. Outcome assessors of the superiority co-
primary outcome will remain blinded to the treatment
group, and there are no circumstances under which allo-
cation will be revealed to them.
Intervention
The trial intervention under test is treatment guided by
the BioFire FilmArray Molecular Diagnostic Machine
Pneumonia Panel (the ‘FilmArray test’), a PCR-based
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system for identifying pathogens causing lower respira-
tory tract infections (LRTI) and their critical antibiotic
resistance genes, coupled with a trial-based prescribing
algorithm adapted to accommodate appropriate site-
specific requirements. The FilmArray tests are
performed in the ICU; they have a set-up time of ap-
proximately 2 min and a run time of 1 h 15min. The
control arm is standard care, which consists of empirical
antibiotics, based on local policy.
Both arms have standard microbiology culture and
susceptibility testing performed, according to local la-
boratory procedures, with results typically available after
48–72 h. These results allow further refinement of ther-
apy in both arms.
To allow both FilmArray and conventional investiga-
tion, all randomised participants require an appropriate
respiratory specimen (sputum, endotracheal aspirate,
bronchoalveolar lavage (BAL) or non-bronchoscopic lav-
age (NBL)) for microbiological investigation, collected
within ±12 h of the decision to change or initiate an
antibiotic for suspected LRTI. The specimen is collected
into two separate containers to create two identical sam-
ples, designated sample 1 and sample 2. For all partici-
pants, sample 1 follows the usual care pathway for
respiratory specimens, and microbiology results are re-
ported when available, as standard. Sample 2 is labelled
with the INHALE trial identifiers and follows one of two
routes dependent upon the treatment group.
For participants in the intervention arm, sample 2 is
tested with the FilmArray Pneumonia Panel in the ICU
as soon as possible (in all cases within 24 h). The results
are reviewed, as soon as they are available, by the treat-
ing clinician, whose antibiotic prescription is directed by
the trial-specific algorithm and local prescribing guide-
lines. It is anticipated that the great majority of interven-
tion participants will receive either only one dose of
empirical treatment or perhaps none before the FilmAr-
ray test result allows treatment to be targeted. The par-
ticipant will continue receiving normal clinical care. For
participants in the control arm, sample 2 is frozen within
24 h, and the FilmArray test is run by either of the two
central laboratories located at the University College
London and University of East Anglia, without the result
being made known to the treating clinicians. Where
consent is given, the spare sample may be retained for
future use in ancillary studies.
Future specimens from the same intervention group
participant may be tested using the FilmArray test pro-
vided the following conditions are met: (i) the partici-
pant has not withdrawn from the trial; (ii) the specimen
is taken as part of the routine care, and a matching spe-
cimen (sample 1) is sent to the microbiology laboratory;
(iii) testing is no less than 72 h after the previous speci-
men and would have been taken regardless of the trial;
(iv) there is enough specimen for the machine testing;
and (v) the participant was randomised to the trial ≤ 21
days previously.
As the intervention happens immediately after ran-
domisation, no special strategies to improve adher-
ence are specified in the trial. All standard care
options are available to clinicians at all times. Barriers
to algorithm adherence are explored and analysed as
part of the behavioural study. Therefore, there are no
special criteria for discontinuing or modifying the
allocated interventions.
Setting
The trial is being run across ICUs at multiple (provision-
ally 12) hospitals with different resistance prevalence
rates, environments and case mixes. They include
London teaching hospitals, regional teaching hospitals,
district hospitals, specialist children’s hospitals and a pri-
vate hospital with an international patient mix. They
have ICUs handling various proportions of medical, sur-
gical and trauma cases. ICU sites are responsible for
identifying, recruiting and consenting participants. Par-
ticipants will remain under the care of their usual health
services throughout their time on the trial (see ISRCTN
registration for a current list of participating sites).
Treatment algorithm
We drafted a master prescribing algorithm based on the
pathogens sought by the FilmArray Panel and current
UK resistance prevalence data as represented in the Brit-
ish Society for Antimicrobial Chemotherapy surveillance
of respiratory pathogens [20]. Site microbiologists, ICU
pharmacists and ICU clinicians were consulted; local
adaptations were allowed, particularly in paediatric prac-
tice, where fewer relevant antibiotics are licensed. Where
possible the algorithm [see Additional File 2] vocates
narrow-spectrum agents: e.g., temocillin versus Entero-
bacterales and flucloxacillin versus MRSA. Alternatives
are offered for patients with mild or severe (anaphylaxis
risk) β-lactam allergy, with the former allowing non-
penicillin β-lactams and the latter eschewing β-lactams
entirely. Where combinations of organisms are detected,
these are sorted hierarchically, with a ‘base’ agent ad-
vised to cover the most inherently resistant species and
additions to cover the further organisms or resistances.
Once local algorithm variations had been agreed upon
with senior site ICU physicians and microbiologists, we
provided training to a wider group of site ICU staff, in-
cluding physicians and research nurses. This was done
face-to-face, using example FilmArray reports, and with
group teaching on how to interpret the algorithm and
which antibiotics to use.
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Eligibility criteria
The following are the inclusion criteria:
1. About to receive an antimicrobial to treat a
suspected LRTI—being either (i) first treatment of a
newly suspected HAP/VAP or (ii) a change in
previous antimicrobials for an LRTI owing to the
deteriorating clinical condition
2. In-patient in a participating ICU/CCU
3. Breathing spontaneously or are intubated for any
reason
4. Hospitalised for > 48 h
5. Able to provide sufficient volume of airway
specimen obtained for routine testing plus 200 μL
for the FilmArray test (samples 1 and 2 above)
The following are the exclusion criteria:
1. Have previously taken part in this trial.
2. Concurrently participating in the active phase
(defined as within 30 days of the primary end point)
of an interventional trial not agreed as acceptable
for co-enrolment by the local PIs of both trials. Par-
ticipants will be permitted to co-enrol in studies
that do not involve an intervention (e.g. observa-
tional studies).
3. Moribund and/or not expected to live for more
than 48 h.
4. Have an existing directive to withhold life-
sustaining treatment, in relation to antibiotic use.
5. Prisoners or young offenders currently in the
custody of the Prison Service or supervised by the
Probation Service.
Participants with COVID-19 can be recruited to the
trial, providing all other criteria are met, critically in-
cluding antibiotic initiation or change predicated on
concern about secondary bacterial infection. This is re-
flective of the current ICU population and aims to make
trial results as generalizable as possible.
Recruitment and consent
Recruitment of participants is from pre-approved ICUs
in England. Participants cannot self-refer; rather, they
are identified as potentially eligible by clinicians in the
ICU.
Pneumonia and other LRTIs in the ICU are life-
threatening, and the decision to administer antibiotics is
taken very quickly; this decision must not be delayed be-
cause of the trial, precluding any attempt to collect fully
informed consent prior to inclusion and treatment or to
elicit consent from distressed relatives. Consent is there-
fore not taken before randomisation and initial delivery
of the intervention, but instead follows a retrospective
process. This is recognised in the European Law [21],
and this decision has been made in consultation with
the trial Patient and Public Involvement (PPI) panel.
Specifically, consent or (more often) assent is taken at
the earliest, or most appropriate, opportunity after the
initial treatment on day 1 and preferably within the next
48 h. Participants or their consultees (in England and
Wales; an unpaid person with an interest in the welfare
of the potential participant or a healthcare professional
who is independent of the project) are given as long as
needed to make an informed decision and the partici-
pant remains in the trial whilst a decision is sought and
as long as there is no objection. The consultee may be a
personal consultee or an independent professional
consultee.
In most cases, it is anticipated that a consultee will be
approached to give assent due to the expected incapacity
of most ICU/CCU patients to give consent. To enable
such patients’ participation in clinical research, the Men-
tal Capacity Act (2005) [22] allows a consultee to grant/
withhold permission until the participant recovers cap-
acity. Should the participant recover capacity, they will
be approached about the trial directly, and in this cir-
cumstance, their consent/refusal overrides the consultee
agreement.
For children (aged 15 years or under), the parents or
guardians of a child are approached to give consent for
their child to participate. Participation is refused in the
event that a child is distressed by participation or does
not assent when they recover capacity.
Data collection
Participants have data collected from their routine care
records, for assessments as shown in Additional file 3:
Table S1.
Data collection continues from day 1 to 21 days after
randomisation or until death if earlier. Daily assessments
stop at day 14, or earlier if the participant is discharged
from the ICU/CCU or dies before day 14. For partici-
pants discharged home prior to 21 days post-
randomisation, a brief telephone interview is conducted
between days 20 and 24, providing consent is given. The
condition of participants still in hospital at 21 days is
assessed from their notes. A medical record check is car-
ried out for the participant’s final date of discharge, or
death noted up to day 28.
Study data are collected and managed using REDCap
[18, 19] electronic data capture tools hosted at the Nor-
wich Clinical Trials Unit (NCTU). Research Electronic
Data Capture (REDCap) is a secure, web-based software
platform designed to support data capture for research
studies, providing audit trails for tracking data manipula-
tion and export procedures and automated export
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procedures for seamless data downloads to common
statistical packages.
Adverse event reporting and monitoring
Adverse events (AEs) and serious adverse events (SAEs)
that are secondary outcomes in the trial do not need to
be reported in an expedited manner but are recorded in
the database. Machine and laboratory errors or issues
producing misleading or wrong results, leading to inef-
fective therapy with potential or actual serious conse-
quences, are to be reported immediately as SAEs. Such
errors may occur as a result of technical problems or by
limitations of the design (e.g. organisms not present on
the panel or specific laboratory reporting practices). In
addition, investigators may report other relevant events.
An independent Data Monitoring Committee (DMC)
has oversight of all trial safety data and can make recom-
mendations as required. No interim analyses are
planned.
Adherence to the protocol is monitored throughout,
as are data quality and completeness.
Outcomes
The trial has co-primary outcomes of the following:
1. Non-inferiority in clinical cure of pneumonia at 14
days post-randomisation. Cure of pneumonia is de-
fined as follows: absence of (i) death where pneu-
monia was considered causative or contributory; (ii)
septic shock, except when associated with a docu-
mented non-respiratory origin of infection; (iii) re-
lapse of pneumonia (relapse is defined as an
infectious pulmonary event, associated with clinical
and radiological signs of HAP or VAP, or a worsen-
ing of 2 points of the baseline multiple organ dys-
function score (SOFA or PELOD-2)); or (iv) other
evidence that the original pneumonia is not cured.
2. Superiority in antimicrobial stewardship at 24 h
post-randomisation is defined as participants on ac-
tive and proportionate antimicrobial therapy within
24 h of clinical diagnosis, where active therapy is
defined as receiving an antimicrobial active against
the organism(s) in vitro and proportionate as active
and not excessively broad spectrum for the patho-
gen(s) identified.
The secondary outcomes comprise the following:
(i) ICU/CCU length of stay, calculated as the time
from randomisation to discharge from the ICU/
CCU
(ii) Number of ventilator-free days within 21 days post-
randomisation
(iii)Mortality, calculated as deaths from any cause
within 28 days of randomisation
(iv) Incidence of septic shock within 21 days of
randomisation
(v) Change in SOFA (ΔSOFA) score from
randomisation to 7 days post-randomisation for
adults
(vi)Change in PELOD-2 (ΔPELOD-2) score from ran-
domisation to 7 days post-randomisation for
children
(vii)Change in pSOFA (ΔpSOFA) score from
randomisation to 7 days post-randomisation for
children
(viii)Proportion of participants on antibiotics active/
inactive against the pathogen(s) found at 24 and 72
h from randomisation
(ix)Proportion of participants on proportionate/
disproportionate antibiotics, in relation to
pathogen(s) found at 72 h from randomisation
(x) Proportion of participants on narrow-spectrum an-
timicrobials at 24 and 72 h from randomisation
(xi)Proportion of participants with specific adverse
events associated with antibiotics within 21 days
from randomisation
(xii)Proportion of participants contracting a secondary
pneumonia within 21 days from randomisation
(xiii)Total per patient antibiotic usage in defined daily
doses (DDDs) by 21 days post-randomisation (all
conditions)
Sample size
The trial aims to recruit 552 patients over a 24-month
recruitment period. Calculation of the required sample
size is based on the co-primary outcomes of clinical cure
at 14 days and antimicrobial stewardship at 24 h. The
trial will investigate non-inferiority in terms of clinical
cure and superiority for antimicrobial stewardship. Cal-
culations aim to achieve 90% power and 5% significance
for the co-primary analyses and allow for up to 5% attri-
tion. Data for the first 100 patients from work package 2
provide estimates for the sample size calculation. For the
non-inferiority outcome, a clinical cure rate of 55% is as-
sumed in both trial arms, and the non-inferiority limit is
defined to be 13% [23–27]. Under standard care, it was
estimated that 53% of patients received antibiotics that
were both appropriate and proportionate within 24 h of
clinical diagnosis, and it is clinically important to im-
prove this by at least 20% (to 73%). The planned sample
size of 552 patients will provide 91% power for the non-
inferiority outcome analysis and 99% power for the su-
periority outcome, resulting in 90% for the co-primary
analysis (0.91 × 0.99 = 0.9), under the conservative as-
sumption of no correlation between the outcomes [28].
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The sample size is not inflated for non-compliance, as
none is expected.
The estimates used for both cure rate and antimicro-
bial stewardship are consistent with those reported in
published studies [24–30].
The trial originally aimed to recruit 466 participants,
but this was updated to 552 to reflect an expected lower
estimated cure rate for pneumonia among COVID-19
patients (postulated at the time to be between 20 and
40% vs. an original estimate, pre-COVID, of 70%). As-
suming a maximum of 30% of the final sample might be
COVID-19 patients, the minimum expected overall cure
rate is 55%, as used in the new sample size calculation.
Estimates were based on the data already collected and
decided in consultation with the principal investigators.
Analysis
The co-primary outcomes will be summarised as the
proportion of participants where:
 Clinical cure was achieved by 14 days after
randomisation;
 Active and proportionate antimicrobial therapy has
been initiated within 24 h of randomisation.
For both outcomes, the effect of the intervention will
be described using a difference in proportions, and an
odds ratio, each calculated with a 95% confidence inter-
val. For the non-inferiority analysis of clinical cure, con-
fidence intervals will be one-sided. Estimates will be
obtained from regression models that allow for study
site. Similar approaches will be used for binary second-
ary outcomes. For continuous secondary outcomes, the
groups will be compared using standard regression
models (where normality assumptions are satisfied) to
obtain the differences in the means allowing for site and
adjusting for baseline values where these are available.
In all superiority analyses, participants will be analysed
on an intention-to-treat basis, regardless of clinicians’
decisions in using the FilmArray test results and the as-
sociated algorithm, or in respect of the antibiotics pre-
scribed. A Microbiology Committee, comprising three
independent members and one member of the study
team, has been set up to review the prescribing
decisions. The committee assesses whether prescribing
is active and proportionate at 24 h and 72 h post-
randomisation for each patient and is blinded to the
study arm. Per-protocol analysis will provide the primary
results for the non-inferiority outcome. The committee
Terms of Reference are shown [see Additional File 4].
Data analysts will not be blinded. A detailed statistical
analysis plan will be finalised before analysis and will in-
clude details of any relevant sub-group or adjusted
analyses. It will be made available, upon request, from
the Trial Management Group.
Health economics evaluation
To determine whether the trial outcomes justify costs, a
cost-effectiveness study will be conducted from a hos-
pital perspective. The outcome measure used will be the
same as the main study co-primary outcome. If the two
arms of the study are found to be equivalent in terms of
clinical cure of pneumonia at 14 days post-
randomisation, a cost-effectiveness analysis will be
undertaken to evaluate the incremental cost per add-
itional patient receiving active and proportionate antibi-
otics within 24 h of clinical decision to prescribe
antibiotics for HAP/VAP. If equivalence in clinical cure
is not established but there is an improvement in anti-
biotic stewardship, interpretation will be more difficult—
a decision-tree model will be used to explore the
implications.
The EuroQol EQ-5D-5L, a generic health-related
quality-of-life measure [31], will be sought from patients
at 21 days to inform the economic evaluation and eco-
nomic model, but will not be suitable for estimating
quality-adjusted life-years (QALYs) for all trial partici-
pants. This is because only the most-recovered subset of
participants will be well enough to complete the EQ-5D-
5L at 21 days, meaning that results will not be represen-
tative of the whole INHALE sample.
Data collection for resource use will be limited to the
patients’ hospital stay, meaning that an ‘NHS and per-
sonal social services perspective’, as recommended by
NICE [32], will not be possible. Costs will be estimated
solely from the perspective of the hospital.
Estimates of costs and effects will be used to calculate
the incremental cost-effectiveness ratios (ICERs), evalu-
ating the incremental cost per additional patient receiv-
ing active and proportionate antibiotics within 24 h of
the decision to prescribe antibiotics for HAP/VAP.
Where appropriate, regression-based methods will be
used to allow for differences in baseline characteristics.
Uncertainty in data will be accommodated by the use of
cost-effectiveness acceptability curves (CEACs), which
estimate the probability that the intervention is cost-
effective at different monetary valuations of the outcome
measure. As costs will be estimated from routinely col-
lected hospital data, we would not expect high rates of
missing data. This approach constitutes a ‘within-trial’
economic analysis, conducted during the clinical trial,
and will constitute the primary economic analysis.
As the study population will be highly heterogeneous
in respect of underlying illness or trauma precipitating
ICU admission, economic evaluation may not be
straightforward. Additionally, the trial will take place
within a short timeframe, so long-run outcomes will not
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be available. Rather, to explore the effect of assumptions
and potential variability, a decision-tree model will be
further developed across the entire INHALE
programme. Data from the literature will be used to esti-
mate the potential long-run health-related quality of life
(HRQoL) effects of HAP/VAP, as well as estimating a
cost/QALY approach. Assumptions as to the health ben-
efits of different pathways and outcomes will allow an
exploration of potential longer-term effects (e.g. poten-
tial effects on antibiotic use, resistance and related
health outcomes). Literature data [33] and clinical opin-
ion will be incorporated where necessary. This decision-
tree model will be used to explore a range of ‘what if’
scenarios, evaluating different consequences of results
from the trial. Assumptions about the consequences of
care provided and of improved antimicrobial steward-
ship will be formulated. This approach is speculative but
will potentially inform decision-makers as to the poten-
tial consequences of rapid microbiological diagnostics.
The results of this model will constitute a secondary
analysis. Details of the proposed methods for the within-
trial analysis and the economic model will be pre-
specified in a health economics analysis plan (HEAP).
Behavioural evaluation
Examining how clinicians make antibiotic decisions in
both arms of the trial is crucial to (i) identifying the be-
havioural factors influencing antibiotic prescribing
(whether appropriate or not); (ii) quantifying the degree
to which the FilmArray test and algorithm influences
doctors’ antibiotic decisions, as to assume 100% compli-
ance with its recommendations is neither appropriate
nor realistic; and (iii) providing a context for RCT find-
ings. Prescriber behaviour will be a key determinant of
the trial outcomes. Rapid molecular diagnostics can only
improve antibiotic stewardship if they are appropriately
applied. Understanding the drivers of, and barriers to,
adoption of rapid molecular-diagnostic-assisted prescrib-
ing (e.g. prescriber trust in FilmArray results) will help
identify the reasons behind trial success/failure.
Data will be collected using a 1-min questionnaire, de-
veloped for INHALE and completed after a specific anti-
biotic decision. This methodology allows for a range of
decisions (e.g. from sites across the UK, out-of-hours de-
cisions) to be consistently captured with minimal disrup-
tion to clinical duties. In the intervention arm, the
questionnaire explores the decision made after receiving
the FilmArray test results. In the control arm, it relates
to the empirical antibiotic decision made directly before
randomisation. The clinician who made the ultimate de-
cision will be asked to complete the survey: intensivists
and specialists working in the ICU will be eligible to par-
ticipate. To minimise recall bias [34], the clinician will
complete the survey as soon as possible after this
decision, but no later than 24 h afterwards. The ques-
tionnaire asks the clinician to indicate factors influen-
cing their decision-making and rate their agreement
with statements about their patient as well as the role of
institutional guidelines, the FilmArray test and the algo-
rithm. Survey design was a collaboration between behav-
ioural scientists, intensivists and microbiologists and was
informed by a literature review, four focus groups and
35 interviews with ICU prescribers.
We will also conduct semi-structured interviews with
clinicians to further explore their perceptions about
using molecular diagnostics in practice. Participants will
be intensivists and microbiologists who have made anti-
biotic decisions with the FilmArray during the RCT.
Clinicians will be encouraged to participate via the
principal investigator at each site, with interview tran-
scripts anonymised. ICUs are time-pressured environ-
ments, and participation rates will be monitored and
changes made if the design proves difficult, but the team
are experienced, and the proposal is based on feasibility
work from earlier work packages. Thematic analysis [35]
will be used to identify clinicians’ perceptual and prac-
tical barriers and enablers to adopting the FilmArray test
and the algorithm. Our findings will aid the development
of evidence-based behavioural strategies encouraging
molecular diagnostic implementation.
Oversight and monitoring
Oversight of the trial is managed by committees, each
with a specific composition and remit, as described in
their Terms of Reference, and summarised as follows.
Trial Management Group (TMG)
Together with the Trial Steering Committee (TSC), this
has the overall oversight of the trial. Chaired by the chief
investigator, it includes (i) clinicians from a broad range
of trial sites; (ii) statistician, programme manager, behav-
ioural study and health economics lead; (iii) members of
the Norwich CTU-based trial team; (iv) sponsor repre-
sentation; and (v) PPI representatives. All trial oversight
groups report back to the TMG which meets at least
every 6 months, though typically every 3 months during
recruitment.
Trial Steering Committee (TSC)
The Programme Steering Committee (PSC) has agreed
to also take up the TSC role, and so is kept appraised on
overall trial progress. Through its independent chair, the
TSC provides advice on all aspects of the trial to the
TMG, sponsor, NIHR as funder and Norwich CTU. The
DMC provides an independent update on data monitor-
ing and safety directly to the TSC chair for consideration
at each meeting. The TSC is composed of five independ-
ent members, including the chair, a PPI representative
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and three non-independent members (the chief investi-
gator, trial statistician and NCTU director). The TSC
meets at least annually, after DMC meetings, but more
frequently during recruitment.
Patient and Public Involvement (PPI) group
The INHALE Public and Patient Involvement Group
(comprising seven members) meets quarterly to discuss
the programme progress and output; this also includes
patient-facing documentation and reviewing all aspects
relating to the management of the INHALE trial. In
addition, two PPI panel members are part of the TMG,
and there is PPI representation on the TSC.
Discussion
ICUs have greater per patient antibiotic use, and so exert
more selection pressures for resistance, than elsewhere
in hospitals, with some (albeit mixed) evidence of corres-
pondingly higher resistance rates [3]. Sub-optimal treat-
ment leads to poorer outcomes for patients, including
side effects from over-treatment and increased mortality
from under-treatment of severe and resistant infections.
The cost to society is also high, both in human terms
and in respect of the cost of hospital stays.
Current microbiology techniques to identify pathogens
and their resistance are slow and outdated and do not
always grow a pathogen despite clinical evidence of in-
fection. There are few new antibiotics reaching the mar-
ket, and recently licensed ones do not wholly overcome
resistance; moreover, they are vulnerable to new modes
of resistance. The UK government’s ‘Contained and
Controlled, 20-year vision for antimicrobial resistance’
[36] confirms the vital need to find alternative, evidence-
based models for antibiotic use.
Molecular diagnostics, such as the FilmArray Pneumo-
nia Panel, offer the potential to achieve this goal by rap-
idly and simultaneously identifying organisms and
critical resistance genes directly from the clinical speci-
men, without culture. The partner algorithm being
trialled together with the FilmArray Panel offers the po-
tential to identify a proportionate antibiotic choice for
each identified pathogen and resistance genotype de-
tected—if clinicians are willing to adopt this approach in
challenging and severely ill ICU patients. If successful,
this work could be extended to other clinical settings,
though the cost advantage, which will be analysed, is
likely to be greatest in ICUs.
In addition, this trial will, to our knowledge, be the
first to explore the human factors that interpose between
a rapid microbiological result and the clinicians’ contin-
gent actions that follow (or not). It has been designed to
capture both the extent of clinicians’ compliance with
the result-driven recommendations, and the reasons
underlying such compliance, or lack of it.
Another novel element of the trial relates to linking a
microbiology result to a suggested antibiotic prescrip-
tion, as suggested by the algorithm, without human
intervention in the decision pathway. To our knowledge,
this is the first instance of advice being developed to
translate the outputs of a complex multiplex microbio-
logical test into prescribing guidance. Whilst it was not
possible to impose a single algorithm at all hospitals,
core principles are successfully retained. We believe this
element of the trial is unique. Not only will the trial test
the utility of the test and algorithm but, in addition, the
behavioural sub-study will reveal new information on
doctors’ attitudes to conventional and machine-driven
results and recommendations.
Trial status
Recruitment began on 5 July 2019; it was paused be-
tween March and July 2020 due to the COVID-19 pan-
demic and resumed in August 2020. The pause for
COVID-19 means that recruitment will be extended be-
yond the original end date of 31 March 2021, stopping
once the sample size is reached. The current protocol
version is 3.0, dated 9 February 2021. An amendment
was required to confirm that COVID-19-positive pa-
tients can now be included routinely in the trial, and this
changed the sample size; the protocol has been amended
previously to add sub-studies (to be reported separately).
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